Abstract
ATS Corp. will report its quarterly results on May 28, 2026 Pre-Market; this preview compiles the latest financial data and forecasts, highlighting expected revenue and earnings trends alongside an assessment of consensus views and what investors should watch in segment performance and margins.
Market Forecast
Market expectations point to revenue of 732.80 million Canadian dollars for the current quarter, implying 6.68% year-over-year growth, with estimated adjusted EPS of 0.44 Canadian dollars, up 18.90% year over year, and forecast EBIT of 78.15 million Canadian dollars, up 9.92%. The company has not formally provided a numerical outlook for gross profit margin or net margin for the quarter; consensus leans toward modest margin stability supported by mix and cost discipline.
The company’s main business remains diversified with material contributions from multiple end uses, and the outlook emphasizes order conversion and backlog execution as the core drivers. Life Sciences is positioned as the most promising segment this period in terms of contribution, with 390.77 million Canadian dollars in revenue last quarter; year-over-year growth by segment was not disclosed in available data.
Last Quarter Review
In the prior quarter, ATS Corp. delivered revenue of 760.70 million Canadian dollars (up 16.67% year over year), a gross profit margin of 29.72%, net profit attributable to the parent company of 29.95 million Canadian dollars, a net profit margin of 3.94%, and adjusted EPS of 0.48 Canadian dollars (up 50.00% year over year).
A notable highlight was operating performance: EBIT reached 79.90 million Canadian dollars, reflecting year-over-year growth of 21.61%, as backlog conversion and operating efficiency offset cost pressures. By business mix, Life Sciences contributed 390.77 million Canadian dollars, Consumer Products 134.04 million Canadian dollars, Food and Beverage 124.81 million Canadian dollars, Energy 72.23 million Canadian dollars, and Transportation 38.80 million Canadian dollars; year-over-year growth by segment was not provided. Net profit declined 11.08% quarter over quarter, indicating that while revenue and EBIT expanded year over year, quarter-to-quarter variability remained present due to mix, delivery timing, and below-the-line items captured in net income.
Current Quarter Outlook
Main business drivers to watch
The company-enterprise level forecast calls for revenue of 732.80 million Canadian dollars, which is a modest step down from last quarter’s reported level but still up 6.68% year over year. The key driver this period is execution on the existing backlog in line with delivery schedules, with a particular emphasis on achieving planned milestones and acceptance on larger programs. Given last quarter’s 29.72% gross margin, the market is watching whether product and program mix can sustain similar margin levels while converting high-value projects and absorbing fixed costs efficiently.
Operating leverage will be important. With EBIT forecast at 78.15 million Canadian dollars (+9.92% year over year), the implied margin trajectory suggests a focus on expense control and disciplined project management. The balance between overhead absorption and volume will determine whether the EBIT improvement translates into incremental margin expansion. Additionally, the estimated 0.44 Canadian dollars adjusted EPS (+18.90% year over year) implies cleaner below-the-line items and a relatively stable tax and interest profile compared with the prior-year period.
Order intake trends and book-to-bill dynamics are a further consideration for near-term sentiment. While the headline numbers are backward-looking with respect to revenue recognition, commentary from sell-side previews points to improving order activity and stabilizing pricing, which would support visibility beyond the current quarter. If these trends materialize in reported new orders and backlog at period end, they can underpin momentum into subsequent quarters and cushion any timing-related revenue variability.
Most promising segment this quarter
Life Sciences remains the largest revenue contributor based on the prior quarter’s mix at 390.77 million Canadian dollars and is likely to be the most consequential segment for this quarter’s results. The segment’s scale provides fixed-cost leverage when delivery cadence is stable, and it often carries a favorable mix profile when high-complexity programs advance toward later milestones. Successful execution here can meaningfully influence consolidated margins and earnings conversion, given the segment’s share of total revenue.
The upcoming print will likely highlight progress on program deliveries and any new-order momentum. If delivery timing aligns with plan, Life Sciences can be a positive swing factor for both revenue and profitability in the quarter. Conversely, timing shifts on large programs would have an outsized impact on consolidated results due to the segment’s size. With year-over-year growth by segment not disclosed, investor focus is likely to be on qualitative updates to delivery schedules, order intake, and profitability drivers within this segment.
Beyond near-term delivery, the segment’s visibility on medium-term pipeline will be closely scrutinized. Positive commentary on order wins or conversion rates would help reinforce the consensus assumption for sustained year-over-year growth through the rest of the fiscal year and provide a buffer against variability in smaller segments.
What could matter most for the stock this quarter
Margin trajectory and order commentary are poised to be the central swing factors for share performance immediately around the print. Even without formal guidance on gross margin, investors will parse the bridge from revenue to EBIT and adjusted EPS to infer whether mix and execution are tracking favorably against last quarter’s 29.72% gross margin baseline. Delivery timing, rework, or cost overruns on larger programs can quickly alter margin perception, and small changes in program economics can have a noticeable impact at the EPS line.
New orders and book-to-bill disclosures will serve as a forward indicator. A book-to-bill ratio at or above unity with evidence of sequential progress would support the case for sustained revenue growth into upcoming quarters. Conversely, if order activity appears choppy or concentrated in lower-margin areas, investors may reassess the durability of the earnings trajectory even if current-quarter results are in line.
Cash conversion and working capital will also be watched. The alignment of milestones and customer payments affects free cash flow profile; stronger collections can amplify the perceived quality of earnings and fund ongoing initiatives without compromising the balance sheet. Coupled with commentary on pricing discipline and cost containment, these factors will shape the market’s interpretation of whether the current 6.68% revenue growth expectation and 18.90% EPS growth estimate are conservative, fair, or optimistic.
Analyst Opinions
Analyst views collected between January 1, 2026 and May 21, 2026 were uniformly constructive, yielding a bullish-to-bearish ratio of 100% to 0%. Multiple institutions reiterated positive stances with supportive rationales anchored in improving order trends, expected margin resilience, and longer-term growth visibility.
- Stifel Canada maintained a Buy rating in April 2026 with a price target of C$52.00, citing the expectation that external policy changes would have limited direct impact on near-term program delivery while the company continues to convert backlog. Their note emphasizes that delivery cadence and project mix should enable steady profitability, aligning with the forecast of 78.15 million Canadian dollars in EBIT and 0.44 Canadian dollars in adjusted EPS.
- TD Cowen reiterated a Buy rating in early 2026 with a target of C$48.00, flagging a rebound in orders, potential margin upside from operational initiatives, and a favorable longer-term growth runway. The firm’s preview suggests that the current-quarter revenue expectation of 732.80 million Canadian dollars (+6.68% year over year) is well supported by backlog and that pricing discipline and efficiency gains can offset input cost variability.
These views collectively focus on two pillars: operational steadiness and momentum in orders. On operational steadiness, analysts expect the company to maintain discipline in project execution, supporting EBIT growth of 9.92% year over year despite a modest sequential revenue step-down from the prior quarter. The implication is that mix, productivity, and overhead control should preserve the pathway from gross profit to EBIT, which in turn underpins the 18.90% year-over-year growth embedded in the EPS estimate.
On momentum, the read-through from recent previews is that order activity and pipeline quality are improving, which matters because revenue recognition trails order intake and program progress. If management confirms healthy demand and a constructive book-to-bill ratio, analysts are likely to view the revenue and earnings baseline as sustainable. This would reinforce the bullish narrative and support valuation, especially if the company pairs delivery progress with stable margin commentary.
The balance of analyst commentary centers on the durability of growth drivers. With the prior quarter showing robust year-over-year growth in revenue (+16.67%) and adjusted EPS (+50.00%), the debate shifts to whether the growth rate normalizes to the mid-single-digit to low-double-digit range implied by the current-quarter forecast. The bullish camp expects normalization rather than re-acceleration to be sufficient for upside, provided execution remains tight and orders continue to replenish backlog at a healthy pace.
Price targets clustered around C$48.00 to C$52.00 suggest confidence in the company’s ability to deliver on near-term forecasts while positioning for continued growth. Within that framework, analysts will assess the quality of the earnings bridge: revenue-to-gross-profit conversion, expense management, and the translation of EBIT into adjusted EPS. Confirmation that last quarter’s net profit margin of 3.94% remains on a stable path would strengthen the bullish case; while management has not guided margin explicitly, consistent execution can mitigate volatility that previously contributed to an 11.08% quarter-over-quarter decline in net profit.
In summary, the majority (bullish) view is that ATS Corp. is positioned to meet or modestly exceed current-quarter expectations driven by orderly backlog conversion, stable-to-improving margins, and constructive order commentary. Should the company validate these assumptions on May 28, 2026 with clear disclosures on deliveries, orders, and cost discipline, the positive setup anticipated by Stifel Canada and TD Cowen would likely remain intact, keeping investor focus on sustaining revenue growth and translating it into consistent earnings and cash flow improvement over the next few quarters.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments